-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NE-3107 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NE-3107 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NE-3107 in Parkinson's Disease Drug Details: NE-3107 (Triolex, HE3286) is under development...
-
Product Insights
Angina (Angina Pectoris) – Drugs In Development, 2023
Global Markets Direct’s, ‘Angina (Angina Pectoris) - Drugs In Development, 2023’, provides an overview of the Angina (Angina Pectoris) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Angina (Angina Pectoris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drugs In Development, 2023’, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Encoberminogene Rezmadenovec in Coronary Artery Disease (CAD) (Ischemic Heart Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Encoberminogene Rezmadenovec in Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details:XC-001 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Encoberminogene Rezmadenovec in Refractory Angina
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Encoberminogene Rezmadenovec in Refractory AnginaDrug Details:XC-001 is under development for the treatment of coronary heart disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INCB-86550 in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INCB-86550 in Bladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.INCB-86550 in Bladder Cancer Drug Details:INCB-86550 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DP-303c in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DP-303c in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.DP-303c in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:DP-303c is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Soft Tissue Sarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Soft Tissue Sarcoma Drug Details: Tislelizumab (Baizean) is a...
-
Track & Monitor
Venture Capital Investments Q3 2023
GlobalData's Venture Capital Investments report provides detailed coverage of the global venture capital investment activity across sectors in Q3 2023, covering key insights and trends.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – encoberminogene rezmadenovec
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry encoberminogene rezmadenovec Drug Details XC-001 is under development for the treatment of coronary heart...